Abvc Biopharma Inc   (ABVC)
Other Ticker:  
Price: $1.2000 $-0.07 -5.512%
Day's High: $1.28 Week Perf: -9.09 %
Day's Low: $ 1.19 30 Day Perf: -4 %
Volume (M): 170 52 Wk High: $ 6.87
Volume (M$): $ 204 52 Wk Avg: $1.09
Open: $1.24 52 Wk Low: $0.33

 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 4
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Abvc Biopharma Inc
Abvc Biopharma Inc is a pharmaceutical company that specializes in the research, development, and commercialization of innovative therapies for various diseases and medical conditions. They focus on biologics, which are medications created from living organisms or contain components of living organisms. Their team of scientists and researchers work diligently to discover and develop novel treatments that can improve the lives of patients worldwide. Abvc Biopharma Inc is dedicated to providing safe and effective solutions to address unmet medical needs and make a positive impact on global healthcare.

   Company Address: 44370 Old Warm Springs Blvd. Fremont 94538
   Company Phone Number: 668-0881   Stock Exchange / Ticker: NASDAQ ABVC
   ABVC is expected to report next financial results on March 30, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Abvc Biopharma Inc

ABVC Biopharma Inc Faces Challenges in Q3 2023: Revenue Decreases by 62.4% and Net Loss per Share Widens

ABVC Biopharma Inc has experienced mixed results in recent months, with a significant gain in stock value over the past five trading days but a substantial drop over the past 90 days. This suggests a volatile performance that raises questions about the company's future prospects.
According to the company's latest financial results, ABVC Biopharma Inc reported disappointing figures for the third quarter of 2023. Revenue decreased by a staggering 62.422% to $0.02 million compared to the same period last year. Additionally, the net loss per share increased from $-0.68 to $-0.82 from the preceding financial reporting period. On a more positive note, revenue doubled to $0.01 million in comparison to the previous quarter.
The recent financial data also reveals a net shortfall of $-3.368 million for ABVC Biopharma Inc, which is an improvement compared to the $-3.777 million deficit in the same financial reporting period last year. This improvement may be indicative of the company's efforts to address its financial challenges and achieve stabilityOne positive signal from the financial report is the increase in accounts receivable, which is often viewed as an indication of rising demand. ABVC Biopharma Inc's accounts receivables were valued at $1.2 million, surpassing the preceding quarter's figures. This suggests that the company has been successful in attracting more customers and generating increased sales.
The recent stock performance, particularly the gain of 15.74% over the past five trading days, may reflect investor optimism surrounding the company's future prospects. However, the larger decline of 34.55% over the past 90 days may signal broader concerns about ABVC Biopharma Inc's stability and profitability.
Looking ahead, it remains to be seen how these financial results will impact ABVC Biopharma Inc going forward. The company's next financial results are expected to be reported on March 30, 2024. It will be crucial for ABVC Biopharma Inc to address its financial challenges, improve its revenue generation, and work towards achieving a consistent and profitable performance. Investors and stakeholders will be closely monitoring the company's progress in the coming months to assess its long-term sustainability and growth potential.

Abvc Biopharma Inc

Catastrophic Decline in Revenue and Alarming Increase in Net Loss for Abvc Biopharma Inc Sends Shockwaves through Pharmaceutical Industry

Subtitle: Wall Street Analysts Concerned as Revenue Plunges and Net Loss Deepens
Date: September 1, 2023
Abvc Biopharma Inc's recently disclosed financial report for the quarter ending June 30, 2023, has sent shockwaves through the pharmaceutical industry. The New York-based biotech company, known for its groundbreaking research, has witnessed a catastrophic decline in revenue and an alarming increase in net loss per share compared to the previous reporting season.
The report states that Abvc Biopharma Inc's revenue plummeted by an astonishing 98.047% to a mere $0.01 million. This sharp decline is in stark contrast to the $0.13 million generated in the previous quarter, reflecting a sequential tumble of 95.237%. It is clear that the company is experiencing substantial challenges that have negatively impacted its financial performance.

Abvc Biopharma Inc

ABVC Biopharma Inc Faces Challenging First Quarter with Cumulative Net Loss of $12 Million; Industry Competitiveness Remains a Concern

Abvc Biopharma Inc Records a Cumulative Net Loss of $-12 Million in the First Quarter of 2023
Abvc Biopharma Inc, a company within the Healthcare sector, has recently recorded a cumulative net loss of $-12 million during the 12 months ending in the first quarter of 2023. This has resulted in a negative return on investment (ROI) of -211.61%, which is not a favorable outcome for the company.
Furthermore, within the Healthcare sector, 810 other companies had a higher return on investment, indicating a lack of competitiveness within the industry. However, the company's overall ROI ranking has progressed in the Mar 31 2023 quarter, coming in at 3830 from the total ROI ranking in the fourth quarter of 2022 at 4670.


Abvc Biopharma Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com